Patient characteristics
|
Age (≥50 years)
|
0.62 (0.35–1.11)
|
0.109*
|
1.16 (0.38–3.54)
|
0.794
|
1.73 (0.52–5.68)
|
0.365
|
Gender (F)
|
2.09 (1.16–3.74)
|
0.014*
|
1.05 (0.35–3.10)
|
0.930
|
1.49 (0.46–4.78)
|
0.502
|
BMI (≥30 kg/m2)b
|
0.90 (0.53–2.33)
|
0.828
|
–
|
–
|
1.01 (0.14–7.18)
|
0.988
|
Triglycerides (≥2.0 mmol/L)
|
0.62 (0.33–1.16)
|
0.135*
|
0.60 (0.19–1.94)
|
0.397
| | |
HIV characteristics
|
HIV duration (≥ 10 years)
|
0.43 (0.21–0.92)
|
0.030*
|
0.14 (0.03–0.79)
|
0.026**
|
0.10 (0.01–0.63)
|
0.014**
|
CDC HIV stage (B&C)c
|
1.52 (0.84-–2.77)
|
0.170*
|
0.81 (0.27–2.39)
|
0.697
|
0.95 (0.30–3.00)
|
0.936
|
CD4 (≤300 cells/mm3)
|
0.57 (0.20–1.64)
|
0.300
|
–
|
–
|
0.09 (0.01–1.04)
|
0.054
|
HIV viral load (≥40 copy/mL)
|
2.55 (1.04–6.2)
|
0.039*
|
10.4 (1.73–2.55)
|
0.011**
|
10.39 (1.79–60.16)
|
0.009**
|
Current use of efavirenz
|
1.46 (0.69–3.06)
|
0.316
|
–
|
–
| | |
Questionnaire assessments
|
Severe LD (LDCD score ≥23 points)d
|
1.02 (0.45–2.33)
|
0.949
|
6.25 (1.33–29.40)
|
0.020**
|
5.22 (1.07–25.37)
|
0.040**
|
HOPS score:e
|
Atrophy observed by patients
|
0.51 (0.27–0.99)
|
0.047*
|
0.49 (0.12–2.07)
|
0.334
|
0.27 (0.05–1.40)
|
0.120
|
Atrophy observed by physicians
|
0.51 (0.26–1.00)
|
0.051*
|
1.13 (0.30–4.26)
|
0.860
|
1.47 (0.37–5.84)
|
0.580
|
Hypertrophy observed by patients
|
1.37 (0.73–2.58)
|
0.325
|
–
|
–
|
0.50 (0.10–2.49)
|
0.396
|
Hypertrophy observed by physicians
|
0.75 (0.38–1.47)
|
0.400
|
–
|
–
|
0.56 (0.13–2.39)
|
0.438
|
Presence of depression (BDI score ≥19)f
|
7.33 (3.64–14.77)
|
0.001*
|
3.62 (0.99–13.27)
|
0.053
|
4.67 (1.08–20.31)
|
0.040**
|
Presence of anxiety (STAI-Y-B score ≥46)g
|
8.44 (4.37–16.30)
|
0.001*
|
7.10 (1.99–25.30)
|
0.003**
|
7.83 (1.91–32.03)
|
0.004**
|